644 related articles for article (PubMed ID: 29502162)
1. Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity.
Klaus G; Taylan C; Büscher R; Schmitt CP; Pape L; Oh J; Driemeyer J; Galiano M; König J; Schürfeld C; Spitthöver R; Schaefer JR; Weber LT; Heibges A; Klingel R
Pediatr Nephrol; 2018 Jul; 33(7):1199-1208. PubMed ID: 29502162
[TBL] [Abstract][Full Text] [Related]
2. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Outcome of Pediatric Patients With Bi-Allelic (Homozygous) Familial Hypercholesterolemia Before and After Initiation of Multimodal Lipid Lowering Therapy Including Lipoprotein Apheresis.
Taylan C; Driemeyer J; Schmitt CP; Pape L; Büscher R; Galiano M; König J; Schürfeld C; Spitthöver R; Versen A; Koziolek M; Marsen TA; Stein H; Schaefer JR; Heibges A; Klingel R; Oh J; Weber LT; Klaus G
Am J Cardiol; 2020 Dec; 136():38-48. PubMed ID: 32946862
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
[TBL] [Abstract][Full Text] [Related]
5. Homozygous familial hypercholesterolemia with severe involvement of the aortic valve-A sibling-controlled case study on the efficacy of lipoprotein apheresis.
Galiano M; Hammersen J; Sauerstein K; Blessing H; Rümmele P; Purbojo A; Schöber M; Moosmann J; Raffelsbauer G; Heibges A; Klingel R
J Clin Apher; 2020 Jun; 35(3):163-171. PubMed ID: 32163632
[TBL] [Abstract][Full Text] [Related]
6. Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis.
Spitthöver R; Röseler T; Julius U; Heigl F; Schettler VJJ; Kühn R; Leebmann J; Raabe A; Knittel M; Schürfeld C; Moesenthin M; Bernhardt WM; Röseler E; Ketteler M; Heibges A; Klingel R
J Clin Apher; 2019 Aug; 34(4):423-433. PubMed ID: 30817043
[TBL] [Abstract][Full Text] [Related]
7. A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry).
Kayikcioglu M; Tokgozoglu L; Yilmaz M; Kaynar L; Aktan M; Durmuş RB; Gokce C; Temizhan A; Ozcebe OI; Akyol TK; Okutan H; Sag S; Gul OO; Salcioglu Z; Yenercag M; Altunkeser BB; Kuku I; Yasar HY; Kurtoglu E; Kose MD; Demircioglu S; Pekkolay Z; Ilhan O
Atherosclerosis; 2018 Mar; 270():42-48. PubMed ID: 29407887
[TBL] [Abstract][Full Text] [Related]
8. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
Vishwanath R; Hemphill LC
J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
[TBL] [Abstract][Full Text] [Related]
9. A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: The Sino-Roman Study.
Stefanutti C; Pang J; Di Giacomo S; Wu X; Wang X; Morozzi C; Watts GF; Lin J
J Clin Lipidol; 2019; 13(4):608-617. PubMed ID: 31255589
[TBL] [Abstract][Full Text] [Related]
10. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
Kawashiri MA; Nohara A; Higashikata T; Tada H; Nakanishi C; Okada H; Konno T; Sakata K; Hayashi K; Inazu A; Mabuchi H; Yamagishi M
Atherosclerosis; 2017 Oct; 265():225-230. PubMed ID: 28926730
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France.
Bruckert E; Kalmykova O; Bittar R; Carreau V; Béliard S; Saheb S; Rosenbaum D; Bonnefont-Rousselot D; Thomas D; Emery C; Khoshnood B; Carrié A
Atherosclerosis; 2017 Feb; 257():130-137. PubMed ID: 28131047
[TBL] [Abstract][Full Text] [Related]
12. High serum triglyceride concentrations in patients with homozygous familial hypercholesterolemia attenuate the efficacy of lipoprotein apheresis by dextran sulfate adsorption.
Drouin-Chartier JP; Tremblay AJ; Bergeron J; Lamarche B; Couture P
Atherosclerosis; 2018 Mar; 270():26-32. PubMed ID: 29407885
[TBL] [Abstract][Full Text] [Related]
13. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
Vrablik M; Raslová K; Vohnout B; Blaha V; Satny M; Kyselak O; Vaclova M; Urbanek R; Maskova J; Soska V; Freiberger T
Atherosclerosis; 2018 Oct; 277():355-361. PubMed ID: 30270071
[TBL] [Abstract][Full Text] [Related]
14. [The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?].
Bláha V; Bláha M; Lánská M; Havel E; Vyroubal P; Zadák Z; Žák P
Vnitr Lek; 2018; 64(1):43-50. PubMed ID: 29498875
[TBL] [Abstract][Full Text] [Related]
15. Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry.
Schmidt N; Dressel A; Grammer TB; Gouni-Berthold I; Julius U; Kassner U; Klose G; König C; Koenig W; Otte B; Parhofer KG; Reinhard W; Schatz U; Schunkert H; Steinhagen-Thiessen E; Vogt A; Laufs U; März W
Atherosclerosis; 2018 Oct; 277():314-322. PubMed ID: 30270065
[TBL] [Abstract][Full Text] [Related]
16. Treatment of homozygous familial hypercholesterolaemia in paediatric patients: A monocentric experience.
Buonuomo PS; Macchiaiolo M; Leone G; Valente P; Mastrogiorgio G; Gnazzo M; Rana I; Gonfiantini MV; Gagliardi MG; Romano F; Bartuli A
Eur J Prev Cardiol; 2018 Jul; 25(10):1098-1105. PubMed ID: 29785886
[TBL] [Abstract][Full Text] [Related]
17. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries.
Reijman MD; Tromp TR; Hutten BA; Hovingh GK; Blom DJ; Catapano AL; Cuchel M; Dann EJ; Gallo A; Hudgins LC; Raal FJ; Ray KK; Sadiq F; Soran H; Groothoff JW; Wiegman A; Kusters DM; ;
Lancet Child Adolesc Health; 2024 Jul; 8(7):491-499. PubMed ID: 38759658
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein apheresis and PCSK9 inhibitors for severe familial hypercholesterolaemia: Experience from Australia and New Zealand.
Page MM; Ekinci EI; Burnett JR; Hooper AJ; Reid N; Bishop W; Florkowski CM; Scott R; O'Brien RC; Watts GF
J Clin Apher; 2021 Feb; 36(1):48-58. PubMed ID: 32911577
[TBL] [Abstract][Full Text] [Related]
20. Disease control via intensified lipoprotein apheresis in three siblings with familial hypercholesterolemia.
Taylan C; Schlune A; Meissner T; Ažukaitis K; Udink Ten Cate FE; Weber LT
J Clin Lipidol; 2016; 10(6):1303-1310. PubMed ID: 27919346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
